AD/PD 2024 Advances in Science & Therapy
International Conference of Alzheimer’s and Parkinson’s diseases and related neurological disorders
March 5-9, 2024 – Lisbon, Portugal
Our Project Leader, Dr. Anaïs Aulas, will orally present the preclinical results on March 6, 2024:
Presentation Title : AMYP53, A FIRST-IN-CLASS INNOVATIVE DRUG PREVENTS THE FORMATION OF TOXIC OLIGOMERS IN ALZHEIMER’S AND PARKINSON’S DISEASES.
Abstract
Gangliosides and lipid rafts are known to be key players in the generation of neurotoxic oligomers formed by Abeta and alpha-synuclein in neural membranes. Abeta and alpha-synuclein in an oligomeric state share a common mechanism that involves formation of Ca2+ permeable pore-like structures in the plasma membrane, inducing Ca2+ homeostasis dysregulation, tau phosphorylation, oxidative stress and synaptic dysfunction that are the hallmarks of Alzheimer’s (AD) and Parkinson’s (PD) diseases. Through its unique design and its ability to selectively target brain gangliosides, AmyP53 blocks the overall neurotoxicity cascade at the earliest membrane binding step.
